57. Inbrija

Acorda Therapeutics
(Acorda Therapeutics)

Active ingredient: levodopa inhalation powder
Disease: Parkinson’s disease
Peak sales estimate: $600 million by 2026
Approved: Dec. 21
Company: Acorda Therapeutics

The scoop: Earlier this year, a delay to the FDA’s Inbrija decision left some industry watchers wondering whether Acorda could pull off a win for the inhaled Parkinson’s drug, which treats so-called “off” periods where symptoms return. Acorda, though, proved its naysayers wrong, and not a moment too soon for the struggling drugmaker. The company recently lost an appeal to keep generics from taking down lead drug Ampyra, meaning it will rely on Inbrija’s rollout revenue to help fill the gap. Investors will have to hope the company can replicate the “fantastic job” it did “on the Ampyra launch years ago,” Jefferies analyst Michael Yee wrote in a note to clients. — Carly Helfand

57. Inbrija

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.